An Infectious Bursal Disease Vaccine, Live (Strain NF8) Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is a live-attenuated avian birnavirus antigen stream supplied as a freeze-dried powder or cake for downstream incorporation into oral and injectable dosage forms. The API is not a finished vaccine; it is a controlled virus concentrate requiring aseptic or low-bioburden handling, stabiliser-compatible formulation, and cold-chain maintenance from lyophilisation through final packaging. Pharmacopoeial control of the finished live avian infectious bursal disease vaccine is described in Ph. Eur. 0587, which includes identity, virus titre, extraneous-agent absence, and safety/potency testing in chickens. Because the antigen is a live replicating virus, terminal sterilisation by gamma irradiation, ethylene oxide, or steam is not applicable. Every excipient, process solvent, and container surface is therefore evaluated for virucidal activity or titre loss rather than only microbial contamination.

Dosage form conversion is not biologically equivalent across the listed presentations. Tablets and capsules demand dry-compaction stress tolerance; injectable solutions demand aseptic reconstitution; drinking-water powders and granules demand aqueous stability for a defined use window; premix presentations demand blend uniformity in feed or mineral carriers. The product specification therefore includes a format-dependent titre recovery study in addition to the common virus identity and purity panel.

What Limits Direct Compression of a Live IBDV API for Tablet Manufacture?

The limiting parameters are compaction pressure, transient adiabatic heating, and blend water activity. Live IBDV is thermolabile; infectivity loss in unprotected powders increases at temperatures above 30 °C and accelerates above 40 °C. Instrumented rotary tablet presses equipped with 10 mm round concave tooling are used in feasibility studies across 8–14 kN compression force; the punch penetration and dwell time are recorded to separate mechanical shear from thermal effects. The powder bed temperature is measured with an infrared pyrometer at the compression zone; excursions above 30 °C require rejection of the trial batch unless a registered freeze-dry cycle has demonstrated higher thermal tolerance for the specific stabiliser.

Direct compression requires excipients with a loss-on-drying value below 1.5% w/w, such as low-moisture microcrystalline cellulose or dibasic calcium phosphate dihydrate. Wet granulation with aqueous binder solutions is a high-risk operation unless the bed temperature is kept below 25 °C and drying is completed within 4 h at a product temperature not exceeding 30 °C. Any coating process must use aqueous film-coating at a bed temperature below 30 °C or cooled inlet air; organic-solvent coating and hot pan coating can reduce live virus titre. Published data for compressed live IBDV tablets are limited, so a development dossier for NF8 tablets must include virus recovery studies after blending, slugging or roll compaction, compression, coating, and stability storage. The acceptance criterion is usually a final titre of not less than 1.0 log10 TCID50 above the minimum protective dose, but the registered release limit is product-specific. Batch-to-batch variability in lyophilised antigen cake moisture, cake collapse, and electrostatic charging during dry granulation should be monitored with near-infrared moisture sensors and in-line particle size analysers.

Freeze-Drying Cycle Boundaries Are Not Equivalent Across Stabiliser Systems

The lyophilised NF8 API is typically filled in glass vials or bulk trays. The freeze-drying cycle is developed around the collapse temperature of the virus-stabiliser matrix; sucrose-based formulations commonly exhibit collapse temperatures between −30 °C and −20 °C. Primary drying is run with a shelf temperature of −15 °C to −5 °C and chamber pressure of 0.1–0.2 mbar, with product temperature maintained below the critical collapse threshold. Secondary drying shelf temperature is brought to 25–30 °C for 4–8 h until residual moisture reaches ≤ 2.0% w/w by Karl Fischer titration according to Ph. Eur. 2.5.12. Stopper closure under nitrogen at ≤ 1.0% v/v residual oxygen protects the dried cake from oxidative damage. These cycle parameters are not universal for NF8; each stabiliser formulation requires freeze-drying microscopy and differential scanning calorimetry to define the glass transition of the maximally freeze-concentrated solute. Batch data must include edge-vial and centre-vial product thermocouple traces because lyophilisation heterogeneity can produce centre-vial collapse while edge vials retain intact cake structure.

For injectable presentations, aseptic filling is performed in an ISO 14644-1 Class 5 environment with grade A in operation comparable to EU GMP Annex 1. Stoppering under vacuum or nitrogen reduces residual oxygen to ≤ 1.0% v/v in the headspace. Container closure integrity is verified by methylene blue dye ingress or helium leak testing; sterility is tested according to Ph. Eur. 2.6.1 or an equivalent harmonised compendial method. The finished cake is reconstituted with sterile water for injection or a manufacturer-designated diluent. No preservative is acceptable because benzalkonium chloride, phenol, and thimerosal are virucidal to live avian birnavirus at typical antimicrobial concentrations.

Strain NF8 Antigenic Class and the Differences from Other IBDV Vaccines

NF8 is assigned to the live intermediate vaccine class when classified by bursal lesion scoring and serological breakthrough in the presence of maternal antibody; published strain-specific comparative data for NF8 are limited in the peer-reviewed literature. The distinction from classical mild live strains is that intermediate vaccines are less neutralised by maternally derived antibody and are used in flocks with higher antibody titres at vaccination. The distinction from hot or intermediate-plus live strains is that the replication and bursal tissue burden are narrower, which lowers the risk of pathological bursal atrophy when administered at the labelled age. Killed IBDV vaccines and oil-emulsion adjuvanted products are inactivated antigen formulations; they require injection, do not replicate in the bursa, and induce a different antibody persistence profile. Live NF8 API must never be combined with killed-virus adjuvant emulsions in the same syringe because the emulsion process and preservatives can inactivate the live fraction.

Unlike recombinant herpesvirus-of-turkey vaccines expressing IBDV VP2, NF8 is a whole-virus live antigen; it replicates in bursal tissue and can induce bursal lesions. This has implications for post-vaccination monitoring and for diagnostic histology. Safety and potency in the finished live vaccine are assessed according to Ph. Eur. 0587; the safety test includes bursa-to-bodyweight ratio or bursal lesion scoring in specific-pathogen-free chickens at a defined age. Potency is determined by vaccinating chickens and measuring serological response or by challenge with virulent IBDV, with the readout expressed as a protective dose. The WOAH Terrestrial Manual chapter for infectious bursal disease provides additional strain characterisation methods, including VP2 gene sequencing and phylogenetic placement.

For spray administration, the lyophilised API is reconstituted in distilled water and applied through a coarse spray cabinet; droplet size is maintained at 50–100 µm to avoid deep respiratory penetration. Syringes and needles used for injection must be rinsed with sterile saline if previously flushed with alcohol. The API is not compatible with chlorhexidine, iodophors, or quaternary ammonium compounds; equipment sanitisation must be followed by a sterile water rinse and drying to prevent residual disinfectant contact. In eye-drop or drinking-water use, the solution is exposed to light and ambient temperature; therefore the use window should not exceed 2 h at ambient temperatures above 20 °C.

Extraneous-Agent Control and Seed Lot Characterisation

Working seed lots for NF8 are established from a master seed and tested for bacterial, fungal, mycoplasma, and viral contamination according to the extraneous-agent methods referenced in Ph. Eur. 0587 for live avian vaccines. The seed is passaged in specific-pathogen-free embryonated chicken eggs or a qualified chicken embryo fibroblast cell line; each production batch is sequenced in the VP2 hypervariable region to confirm identity. The live virus titre is determined by limiting dilution assay in embryonated eggs or cell culture and is expressed as log10 TCID50 or EID50 per dose or per milligram of dried API. The API must be free of avian leucosis virus, reticuloendotheliosis virus, and other adventitious agents; the test design follows the live vaccine monograph and WOAH requirements for avian viral vaccines.

The finished product is stored at 2–8 °C in the dry state. Storage at −20 °C is used for some bulk intermediates but must be validated for each formulation. Freeze-thaw cycles of reconstituted liquid are not compatible with live virus titre; any excursion above 25 °C for more than 2 h during transport requires titre verification before use. Data loggers are placed against the container wall to document temperature excursions, not in the surrounding air, because thermal mass differences can conceal short-term surface warming.

Water sanitation is a critical process variable for powders and oral solutions. Free chlorine above 0.1 mg/L, chloramines above 0.5 mg/L, and copper or zinc ions from metal plumbing can reduce live virus titre by more than 1.0 log10 within 30 min in development studies. Field manuals use skimmed milk powder at 2 g/L as a competitive protein neutraliser; sodium thiosulfate is used only if the chlorine residual is measured and the dose calculated from the measured free chlorine concentration. The vaccine solution must be distributed in plastic or stainless steel tanks, not galvanised or copper vessels. Tanks are covered and protected from direct sunlight. After reconstitution, the product is used within 2 h at ambient temperatures above 20 °C; published data for NF8-specific aqueous stability is limited, so site-specific verification is required.

For dry premix and granule formats, the API is generally blended with lactose monohydrate, dextran, or skimmed milk powder. The blend is not pelleted at temperatures above 60 °C because the live virus titre decays rapidly in moist heat; cold pelleting or post-pellet spray-on application is used if a pelleted feed presentation is required. Final powder moisture is held below 2.0% w/w; water activity below 0.4 a_w improves storage stability. The product is packaged with desiccant and stored at 2–8 °C. Freeze-thaw cycles are not used for dry premix but must be avoided for reconstituted liquids.

Table 1. Format-dependent critical control matrix for live NF8 API processing.

When Capsule Filling with Live Virus Powder Is Applied to NF8 API

Hard-gelatin capsule filling introduces fewer mechanical stresses than tableting, but the main risks are hygroscopic gelatin shell moisture transfer and electrostatic powder segregation. Capsule bodies must be conditioned to 10–15% w/w shell moisture to prevent brittleness; powder fill should have water activity below 0.3 a_w to avoid moisture exchange with the shell. Automatic capsule machines with dosator or tamping-pin systems operate at fill speeds where dust generation can carry live virus; containment should follow biosafety level 2 practices for veterinary viral antigens. The filled capsules are not enteric coated unless an aqueous enteric system is used at bed temperature below 30 °C. Analytical release includes content uniformity by weighing and virus titre by TCID50 or EID50 per capsule; disintegration is tested according to Ph. Eur. 2.9.1, but the disintegration medium must not contain disinfectants.

Published data for NF8 capsules are limited; therefore the process parameter window must be verified using placebo and active development batches. Residual moisture in the capsule shell and powder blend is measured with Karl Fischer after 48 h at 25 °C and 60% RH; any increase above 1.0% w/w relative to initial values triggers a titre verification study. Capsule storage is at 2–8 °C in sealed aluminium pouches with desiccant.

The oral solution format is prepared by reconstitution of the lyophilised powder in potable water or buffer, not as a shelf-stable multivalent liquid. Long-term aqueous storage of live NF8 is contraindicated because infectivity declines by more than 0.5 log10 within 24 h at 25 °C in unprotected dilute solutions. Where a ready-to-use solution is registered, it is typically supplied frozen at −20 °C or in a stabiliser system with hydrolysed protein and sucrose; the product must not be refrozen after thawing and must be used within 2 h at farm level. The NF8 API differs from inactivated IBDV suspension concentrates in that it cannot be pooled with oil adjuvants, cannot be preserved with common antimicrobial agents, and requires cold-chain maintenance at 2–8 °C in the dry state. For multi-dose injection vials, the in-use period after first broach is controlled by the marketing authorisation and is commonly not more than 4 h; residual volume is inactivated with disinfectant before disposal.